Meeting
2012 ASCO Annual Meeting
Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results.
Authors
Jaafar Bennouna
Institut de Cancerologie de l'Ouest/Site René Gauducheau, Nantes, France
Jaafar Bennouna , Petr Zatloukal , Maciej Jerzy Krzakowski , Jens Kollmeier , Alain Riviere , Eric Dansin , Monika Serke , Adolfo G. Favaretto , Libor Havel , Stephanie Malasse , Fabienne Biville-Hedouin , Eng Huat Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
2009-012001-19
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7575)
DOI
10.1200/jco.2012.30.15_suppl.7575
Abstract #
7575
Poster Bd #
49A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Prospective randomised phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) with nonsquamous (Non SCC) histological type. NAVoTRIAL01: Final results.
First Author: Jaafar Bennouna
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2018 ASCO Annual Meeting
NORA trial (GECP 15/02): First efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC).
First Author: Dolores Isla
Poster
2023 ASCO Annual Meeting
First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update and outcomes by tumor histologic subtype (THS).
First Author: David Paul Carbone